Oruka Therapeutics announced that 63.5% of patients achieved complete skin clearance at week 16 in its Phase 2a trial, with no serious adverse effects reported.
The company says Orka-001 demonstrated higher efficacy than all other inhibitors of its kind and was well tolerated, matching placebo safety profiles.
Oruka plans to release longer-term data in the second half of 2026 and expects results from a separate Phase 2b trial in 2027, as shares have more than doubled this year.
What hurdles remain for Orka-001 before it can reach patients and challenge market leaders?
Oruka’s stock has tripled. Is this a biotech bubble or the future of chronic disease treatment?
Is complete skin clearance from one yearly shot more valuable to patients than a daily pill?
Could this long-acting antibody platform be the key to treating other autoimmune diseases beyond psoriasis?
How will insurers weigh the high price of a yearly shot against cheaper, frequent treatments?